Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 12.00 RMB per 10 shares (tax included) for all shareholders, with adjustments based on the number of shares held in the company's repurchase account [2][4]. Summary by Sections 1. Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting on May 16, 2025, and will distribute cash dividends without issuing bonus shares or capitalizing reserves [2]. - The total share capital for the distribution is 232,520,957 shares, excluding 13,034,741 shares held in the repurchase account, resulting in a base of 219,486,216 shares for the cash dividend calculation [2][4]. 2. Cash Dividend Details - Each shareholder will receive a cash dividend of 12.00 RMB per 10 shares (tax included), with different tax treatments for various types of shareholders [2][4]. - The total cash dividend amount is calculated as 263,383,459.20 RMB, based on the participating share capital multiplied by the distribution ratio [4]. 3. Ex-Dividend Date and Record Date - The record date for the distribution is set for June 11, 2025, and the ex-dividend date is June 12, 2025 [3]. 4. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies or other custodians [3]. 5. Adjustments and Calculations - The ex-dividend price will be adjusted based on the cash dividend amount, calculated as 1.1327299 RMB per share, which will be deducted from the closing price on the record date [4].

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing investment in low-risk financial products up to 230 million yuan, aiming to enhance fund utilization efficiency and increase returns for the company and its shareholders [1][4]. Group 1: Investment Management - The company will use no more than 230 million yuan of idle raised funds for investments in safe, liquid, and principal-protected financial products or time deposits, with the funds being available for rolling use within 12 months from the shareholder meeting approval [1]. - A dedicated settlement account for the raised funds has been established, ensuring that these funds will only be used for cash management and will not be mixed with non-raised funds [3]. Group 2: Risk Control Measures - The company will adhere to prudent investment principles, selecting reputable financial institutions with strong risk control measures for cash management [2]. - The company will conduct timely analysis and monitoring of the financial products' performance, taking necessary actions if risks to fund safety are identified [2]. - The audit department will oversee the use and custody of funds related to this cash management initiative, ensuring compliance and risk evaluation [2]. Group 3: Impact on Operations - The establishment of the dedicated settlement account and the planned cash management will not alter the intended use of raised funds, ensuring that daily operations and investment projects remain unaffected [2]. - The company emphasizes that this strategy is aimed at safeguarding the required funds for investment projects while enhancing the overall safety and efficiency of fund usage [2].

证券代码：002932 证券简称：明德生物 公告编号：2025-033 武汉明德生物科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日 召开第四届董事会第十九次会议、第四届监事会第十六次会议，2025 年 5 月 16 日召开 2024 年年度股东大会审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意公司使用不超过 23,000.00 万元（含）的闲置募集资金投资 安全性高、流动性好、保本型的理财产品或定期存款、结构性存款，在上述额度 内，资金可在公司股东大会审议通过之日起 12 个月内滚动使用。董事会授权总 经理行使该项投资决策权并由财务负责人负责具体购买事宜。具体内容详见公司 于 2025 年 4 月 25 日在巨潮资讯网披露的《关于使用部分闲置募集资金进行现金 管理的公告》（公告编号：2025-021）。 集资金进行现金管理购买理财产品的结算，不会用于存放非募集资金或用作其他 用途。 二、投资风险 ...

证券代码：002932 证券简称：明德生物 公告编号：2025-032 武汉明德生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）本次实施的利润 分配方案按公司现有总股本 232,520,957 减去公司回购专户中持有的股份数量 13,034,741 股为基数，向全体股东每 10 股派发现金红利 12.00 元（含税），不送 红股，不以公积金转增股本。 2、因公司回购股份不参与分红，本次权益分派实施后，根据股票市值不变 原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比 例将减少。因此，本次权益分派实施后除权除息价格计算时，每股现金红利（含 税）应以1.1327299元/股计算（每股现金红利=现金分红总额/总股本，即1.1327299 元/股=263,383,459.20 元÷232,520,957 股）（结果取小数点后七位，最后一位直 接截取，不四舍五入），按公司总股本（含回购股份）折算每 10 股现金分红金 额（含税）为 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and industry comparison [1][2] - As of June 3, the closing price of Mingde Biological was 19.71 yuan, with a PE ratio of 118.10, marking a new low in 111 days, and a total market capitalization of 4.583 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of April 18, 2025, the number of shareholders for Mingde Biological was 25,248, a decrease of 345 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of the company includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, representing a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]

证券代码：002932 证券简称：明德生物 公告编号：2025-031 武汉明德生物科技股份有限公司 对外投资进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、进展情况说明 基于发展战略调整，经全体合伙人协商一致，全体合伙人同比例减少认缴出 资额。近日公司收到青柠基金完成工商变更登记通知，认缴出资额由 12,000 万 元人民币变更为 9,960 万元人民币，其中，公司认缴出资额由 2,450 万元人民币 减少为 2,033.50 万元人民币。合伙人认缴出资变更情况如下： | 合伙人名称 | 变更前认缴出 | 变更前出资 | 变更后认缴出 | 变更后出 | | --- | --- | --- | --- | --- | | | 资额（万元） | 比例 | 资额（万元） | 资比例 | | 武汉明德生物科技股份有限公司 | 2,450 | 20.42% | 2,033.50 | 20.42% | | 湖北长创产业投资基金有限公司 | 2,450 | 20.42% | 2,033.50 | 20.42% | | --- | --- | --- | -- ...

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company was 16.37% [1] Market Position - The company's current stock price is 18.75 yuan, with a decline of 1.16% [1] - The rolling price-to-earnings (PE) ratio is 112.35, significantly higher than the industry average of 48.92 and the industry median of 35.68, placing the company at the 108th position in the industry ranking [1][2] - The total market capitalization of the company is 4.36 billion yuan [1] Institutional Holdings - As of the first quarter of 2025, six institutions hold shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.84 million shares valued at 250 million yuan [1]

Group 1 - The core viewpoint of the articles indicates that Mingde Biological's stock is currently underperforming with a closing price of 19.0 yuan, down 1.91%, and a rolling PE ratio of 113.85 times, significantly higher than the industry average [1][2] - The total market capitalization of Mingde Biological is reported at 4.418 billion yuan, ranking 108th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 4.511 million yuan in major funds on May 22, with a total outflow of 11.4719 million yuan over the past five days, indicating a negative trend in investor sentiment [1] Group 2 - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as providing information solutions for critical care and third-party medical testing services [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, but reported a net loss of approximately 3.662988 million yuan, a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]

证券代码：002932 证券简称：明德生物 公告编号：2025-030 武汉明德生物科技股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 3、会议召开方式： 本次股东大会采取现场投票、网络投票相结合的方式召开。 （1）现场投票：股东本人出席现场会议或者通过授权委托书委托他人出席 现场会议； （1）现场会议：2025年5月16日（星期五）14:00开始 （2）网络投票时间：2025年5月16日 其中通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月 16日（星期五）上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为：2025年5月16日（星期五）9:15-15:00期间 的任意时间。 2、现场会议召开地点：武汉市东湖新技术开发区九龙中路77号武汉明德生 物科技产业园1 ...

北 京 大 成 （ 武 汉 ） 律 师 事 务 所 关 于 武 汉 明 德 生 物 科 技 股 份 有 限 公 司 2024 年 年 度 股 东 大 会 的 法 律 意 见 书 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范性文 件的要求，北京大成（武汉）律师事务所（以下简称"本所"）接受武汉明德生物 科技股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2024 年年度 股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序及表决结果发表法律意见，并不对本次股东大会所审 议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法律意见书随 本次股东大会其他信息披露资料一并公告。 北 京 大 成 （ 武 汉 ） 律 师 事 务 所 www.dentons.cn 武汉市江岸区建设大道 718 号浙商大厦 10 层（430015） 10/F, Zheshang ...